Dr Reddy’s Debuts Two Revlimid Exclusives As Part Of Complete Launch In US
End Of Teva Exclusivity Period Opens Door For Several Lenalidomide ANDA Approvals
Dr Reddy’s Laboratories is set to reap the rewards of a significant US generic launch – albeit one with a limited volume caveat decreed by a patent-litigation settlement deal – after it began selling its generic of Bristol Myers Squibb’s multi-billion-dollar blockbuster Revlimid.
